BTIG analyst Marie Thibault reiterated a Buy rating on iCAD (ICAD) today and set a price target of $25.00. The company’s shares closed last Monday at $16.68.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 67.7% and a 57.4% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for iCAD with a $23.25 average price target.
See today’s analyst top recommended stocks >>
iCAD’s market cap is currently $418.7M and has a P/E ratio of -50.80. The company has a Price to Book ratio of 9.48.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
iCAD, Inc. engages in the provision of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer. It operates through the Cancer Detection and Cancer Therapy business segments. The Cancer Detection segment includes image analysis and clinical decision support solutions for mammography, breast tomosynthesis, and computed tomography imaging. The Cancer Therapy segment offers an isotope-free cancer treatment platform technology. The company was founded in 1984 and is headquartered in Nashua, NH.
Read More on ICAD:
